|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:bfsLayer
|
5
|
|
gptkbp:bfsParent
|
gptkb:dabrafenib
gptkb:Cotellic
|
|
gptkbp:activities
|
MEK inhibitor
|
|
gptkbp:appointed_by
|
oral tablet
|
|
gptkbp:approves
|
gptkb:FDA
|
|
gptkbp:brand
|
gptkb:Mekinist
|
|
gptkbp:can_be_used_with
|
gptkb:dabrafenib
gptkb:cobimetinib
|
|
gptkbp:class
|
antineoplastic agent
|
|
gptkbp:clinical_trial
|
Phase III
monotherapy or in combination therapy
|
|
gptkbp:composed_of
|
gptkb:chemical_compound
|
|
gptkbp:contraindication
|
pregnancy
lactation
|
|
gptkbp:developed_by
|
gptkb:Glaxo_Smith_Kline
|
|
gptkbp:dosage_form
|
gptkb:tablet
2 mg once daily
|
|
gptkbp:effective_date
|
gptkb:2013
|
|
gptkbp:excretion
|
biliary
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
trametinib
|
|
gptkbp:indication
|
BRAF V600 E or V600 K mutation-positive melanoma
|
|
gptkbp:ingredients
|
C19 H19 Cl F3 N3 O3 S
|
|
gptkbp:interacts_with
|
other cancer therapies
CY P3 A4 inducers
CY P3 A4 inhibitors
|
|
gptkbp:invention
|
patented
|
|
gptkbp:is_atype_of
|
L01 X E24
|
|
gptkbp:is_used_for
|
treatment of melanoma
|
|
gptkbp:lifespan
|
about 4.5 hours
|
|
gptkbp:manager
|
oral
|
|
gptkbp:marketed_as
|
gptkb:Mekinist
|
|
gptkbp:metabolism
|
hepatic
|
|
gptkbp:monitors
|
0 A0 B1 D1 F1 D
|
|
gptkbp:pharmacokinetics
|
oral bioavailability
inhibition of MEK pathway
|
|
gptkbp:research_areas
|
cancer therapy
|
|
gptkbp:safety_features
|
liver function tests
skin examinations
complete blood counts
cardiac function tests
|
|
gptkbp:side_effect
|
gptkb:hospital
fatigue
nausea
diarrhea
rash
thromboembolic events
interstitial lung disease
hypersensitivity reactions
elevated liver enzymes
ocular toxicity
|
|
gptkbp:social_structure
|
gptkb:drug
|
|
gptkbp:targets
|
ME K1
ME K2
|
|
gptkbp:tdp
|
not applicable
|
|
gptkbp:type_of
|
871700-17-3
|